Asia-Pacific Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel

The Asia Pacific epilepsy market was valued at US$ 2.20 billion in 2022 and is expected to reach US$ 3.14 billion by 2030; it is estimated to register a CAGR of 4.6% from 2022 to 2030.

Surge in Awareness Program Conducted by Organizations Boosts Asia Pacific Epilepsy Market

Growing awareness about epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, the American Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment. Numerous awareness campaigns are conducted by organizations worldwide to spread awareness regarding the condition and available treatment.

In 2023, on the Purple Day of Epilepsy, Aster Prime Hospitals in Hyderabad (India), in collaboration with the Walkers Association of Krishna Kant Park, held an awareness activity. One hundred fifty participants in total, including walkers and yoga practitioners, attended this session. Additionally, in order to improve the quality of life for Australians living with epilepsy, Epilepsy Action Australia offers a variety of tools and services aimed at raising awareness, educating, and equipping individuals with the necessary skills. Thus, such initiatives and awareness campaigns result in an increase in epilepsy diagnoses and treatments, offering lucrative growth opportunities to the market.

Asia Pacific Epilepsy Market Overview

The Asia Pacific epilepsy market is analyzed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively.

Asia Pacific Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Market Segmentation

The Asia Pacific epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Asia Pacific epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Asia Pacific epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Asia Pacific epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Asia Pacific epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Asia Pacific epilepsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Asia Pacific epilepsy market.